Literature DB >> 21841948

Endometrioid adenocarcinoma presenting in a patient 18 years after hysterectomy: a potential hazard of unopposed oestrogen therapy.

Alvaro Bedoya Ronga1, Salim K Najia, Neil Sahasrabudhe, Richard Prescott, Felicia Elena Buruiana, Alexander Heazell.   

Abstract

We present a case of endometrioid adenocarcinoma arising from extragonadal endometriosis 18 years after total abdominal hysterectomy with bilateral salpingo-oophorectomy. After the primary surgery the patient received 11 years of unopposed oestrogen hormone replacement therapy. She presented with symptoms of urinary retention and pelvic mass. Following resection, histopathology identified the mass as an endometrioid adenocarcinoma. The association between persistent endometriosis and the development of endometrial cancer are discussed here together with the risks of unopposed oestrogen in the development of such lesions.

Entities:  

Year:  2009        PMID: 21841948      PMCID: PMC3027906          DOI: 10.1136/bcr.05.2009.1829

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

1.  Malignancy arising in extraovarian endometriosis during estrogen stimulation.

Authors:  F Gücer; D Pieber; M G Arikan
Journal:  Eur J Gynaecol Oncol       Date:  1998       Impact factor: 0.196

2.  Bias versus causality: interpreting recent evidence of association between endometriosis and ovarian cancer.

Authors:  Paola Viganò; Edgardo Somigliana; Fabio Parazzini; Paolo Vercellini
Journal:  Fertil Steril       Date:  2007-02-22       Impact factor: 7.329

Review 3.  Hormone replacement therapy in women with past history of endometriosis.

Authors:  N F Soliman; T C Hillard
Journal:  Climacteric       Date:  2006-10       Impact factor: 3.005

4.  Cancer risk after a hospital discharge diagnosis of endometriosis.

Authors:  L A Brinton; G Gridley; I Persson; J Baron; A Bergqvist
Journal:  Am J Obstet Gynecol       Date:  1997-03       Impact factor: 8.661

5.  The familial risk of breast cancer in women with endometriosis from Yale series.

Authors:  Ioannis M Matalliotakis; Hakan Cakmak; Neal Mahutte; Anastasia G Goumenou; Georgios Koumantakis; Aydin Arici
Journal:  Surg Oncol       Date:  2008-05-05       Impact factor: 3.279

6.  The risk of cancer and the role of parity among women with endometriosis.

Authors:  A Melin; P Sparén; A Bergqvist
Journal:  Hum Reprod       Date:  2007-09-13       Impact factor: 6.918

Review 7.  Malignancy arising in extragonadal endometriosis: a case report and summary of the world literature.

Authors:  J J Brooks; J E Wheeler
Journal:  Cancer       Date:  1977-12       Impact factor: 6.860

8.  Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis.

Authors:  Francesmary Modugno; Roberta B Ness; Glenn O Allen; Joellen M Schildkraut; Faith G Davis; Marc T Goodman
Journal:  Am J Obstet Gynecol       Date:  2004-09       Impact factor: 8.661

Review 9.  Endometriosis and the development of malignant tumours of the pelvis. A review of literature.

Authors:  Toon Van Gorp; Frederic Amant; Patrick Neven; Ignace Vergote; Phillipe Moerman
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2004-04       Impact factor: 5.237

Review 10.  Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence.

Authors:  Edgardo Somigliana; Paola Vigano'; Fabio Parazzini; Sandra Stoppelli; Erika Giambattista; Paolo Vercellini
Journal:  Gynecol Oncol       Date:  2006-02-13       Impact factor: 5.482

View more
  2 in total

Review 1.  Malignant transformation of persistent endometriosis after hysterectomy.

Authors:  Naif A Bawazeer; Hatim M Al-Jifree; Abdulrahim M Gari
Journal:  Saudi Med J       Date:  2014-11       Impact factor: 1.484

2.  Extraluminal bowel obstruction by endometrioid adenocarcinoma 34 years post-hysterectomy: risks of unopposed oestrogen therapy.

Authors:  Tim T Wang; Richard J Jabbour; Joanna C Girling; Peter J McDonald
Journal:  J R Soc Med       Date:  2011-10       Impact factor: 5.344

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.